## BEST AVAILABLE COM



## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/075,718	02/12/2002	Allan Y. Chen	063004-5505 US	1621
7	590 08/10/2005		EXAM	INER
Nan Wu M.D	., PH.D., J.D.		KIM, JEN	NIFER M
Morgan, Lewis	& Bockius LLP		<u></u>	
One market Str			ART UNIT	PAPER NUMBER
Spear Street To	ower		1617	
San Francisco, CA 94105		DATE MAILED: 08/10/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

Su	pplem	ental. owability
Notice	of Alle	owability

Application No.	Applicant(s)		
10/075,718	CHEN, ALLAN Y.		
Examiner	Art Unit		
Jennifer Kim	1617		

Supplement	10/075,718 CHEN, A		ALLAN Y.	
Notice of Allowability	Examiner	Art Unit		
	Jennifer Kim	1617		
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	dication. If not includ will be mailed in due	ed course. THIS	
1. $\boxtimes$ This communication is responsive to <u>May 10, 2005</u> .				
2. X The allowed claim(s) is/are 42-46 and 48 (renumbered as 1				
3. The drawings filed on 12 February 2002 are accepted by the	e Examiner. (minor changes	made by the E	eumirer.)	
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority un</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have</li> </ul>	der 35 U.S.C. § 119(a)-(d) or (f).	<b>V.</b>		
<ol><li>Certified copies of the priority documents have</li></ol>	been received in Application No	·		
<ol><li>Copies of the certified copies of the priority doc</li></ol>	uments have been received in this r	national stage applica	tion from the	
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:				
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a reply ( ENT of this application.	complying with the re	quirements	
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	tted. Note the attached EXAMINER's reason(s) why the oath or declarate	S AMENDMENT or N tion is deficient.	IOTICE OF	
6. CORRECTED DRAWINGS ( as "replacement sheets") must	be submitted.			
(a) ☐ including changes required by the Notice of Draftsperso	on's Patent Drawing Review ( PTO-	948) attached	,	
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date				
(b)  including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment or in the O	ffice action of		
Identifying indicia such as the application number (see 37 CFR 1.) each sheet. Replacement sheet(s) should be labeled as such in the	34(c)) should be written on the drawin e header according to 37 CFR 1.121(d	gs in the front (not the	back) of	
<ol> <li>DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F</li> </ol>	it of BIOLOGICAL MATERIAL m	nust be submitted. I	Note the	
Attachment(s) 1. □ Notice of References Cited (PTO-892)	5. Notice of Informal Pa	atent Application (PTC	O-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary			
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./Mail Date B), 7. ⊠ Examiner's/Amendm	e nent/Comment		
Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit	ا إلام يو 8. 🔲 Examiner's Stateme	mental nt of Reasons for Allo	owance	
of Biological Material	9.  Other			

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Application/Control Number: 10/075,718

Art Unit: 1617

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the specification page 6, line 16, delete "Figure 3A shows" and insert - - - Figures 3A1, A2, A3, and A4 show- - - - -.

In the Drawings, delete FIGURES 1, 2, 3, 4 and 5 and replace with the attached Figures 1-5 herein.

#### Remarks

The above amendment places this case in condition for allowance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sreenivasan Padmanabhan Supervisory Examiner Art Unit 1617

Jmk July 5, 2005



INDO derivative	R <sub>1</sub>	$R_2 = R_3$	
F1 (rebeccamycin)	NH	Cl	
F5	0	Н	
F7 (also known as R-3)	NOH	Н	
F43	NCH <sub>3</sub>	Cl	
F44	NCH <sub>3</sub>	Н	
F71	NH	Н	





FIGURE 2



B


Parameters	RT alone	F1	F5	F7	CPT
$\mathbf{D_0}$	1.8	1.8	1.8	1.5	1.8
$\mathbf{D}_{\mathbf{q}}$	2.7	0.0	0.0	0.7	0.8

FIGURE 3

Drug Concentration (µM)

40

50



# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.